Drug Pricing
Commentary
Trump’s drug pricing executive orders harmful to patients — will hinder development of new drugs
President Trump issued four executive orders Friday that he said will lower drug prices — but in reality, three of the orders will cause far more harm than good and represent electioneering at its worst. The three harmful executive orders allow the importation of drugs from Canada, reduce the price ...
Sally C. Pipes
July 24, 2020
Drug Pricing
Sally Pipes and Lars Larson Examine Trump Ex. Orders on Drug Pricing
Sally C. Pipes joins the Lars Larson Show to question the Trump administration’s latest action on drug pricing. President Trump plans to sign an executive order on Friday, July 24 that puts limits on drug pricing in the United States. Pipes explains that 90 percent of drugs are generic and ...
Sally C. Pipes
July 24, 2020
Commentary
Executive Order On Drug Price Controls Would Backfire
Rumor has it that President Trump will soon issue a sweeping executive order to lower prescription drug prices by fiat. Nothing is set in stone. But the order would reportedly index the government’s reimbursements for medicines to the prices that Britain, France, Canada, and other developed nations pay. Since all those nations ...
Sally C. Pipes
July 22, 2020
Commentary
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
Wayne Winegarden
July 20, 2020
Drug Pricing
What We’re Watching – July 17
Rowena Itchon – 102-year-old woman survives 1918 pandemic, COVID-19 Gerri Schappals is 102, and survived the Spanish flu, cancer, and COVID-19 – an inspiration to us all. Ben Smithwick – The Black Swan Economy Jonathan Coslet, Senior Partner & Chief Investment Officer at TPG Capital, and Stanford Professor John B. ...
Pacific Research Institute
July 17, 2020
Commentary
Coronavirus drug cost – Ignore critics. Here’s why the price is right
Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Sally C. Pipes
July 6, 2020
Commentary
Learning The Right Lessons From The Race For An Effective Covid-19 Treatment
On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Wayne Winegarden
June 30, 2020
Commentary
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
Sally C. Pipes
June 23, 2020
Blog
What We’re Watching – June 19
Tim Anaya – How Medicines in the U.S. are Sold In the latest video in PRI’s “Escape the Drug Pricing Maze” video, the Professor and Pete reach the most difficult part of their journey: understanding how medicines are sold. It’s a complex system that hurts patients and at times exposes ...
Pacific Research Institute
June 19, 2020
Blog
What We’re Watching – June 5
Tim Anaya – Digging Up Ways to Lower Costs for High Value but Expensive Drugs In the latest video in the “Escape the Drug Pricing Maze” video, Sage the Detective Dog digs up clues on biologics and gene therapies – drugs that offer tremendous value for patients but are some ...
Tim Anaya
June 5, 2020
Trump’s drug pricing executive orders harmful to patients — will hinder development of new drugs
President Trump issued four executive orders Friday that he said will lower drug prices — but in reality, three of the orders will cause far more harm than good and represent electioneering at its worst. The three harmful executive orders allow the importation of drugs from Canada, reduce the price ...
Sally Pipes and Lars Larson Examine Trump Ex. Orders on Drug Pricing
Sally C. Pipes joins the Lars Larson Show to question the Trump administration’s latest action on drug pricing. President Trump plans to sign an executive order on Friday, July 24 that puts limits on drug pricing in the United States. Pipes explains that 90 percent of drugs are generic and ...
Executive Order On Drug Price Controls Would Backfire
Rumor has it that President Trump will soon issue a sweeping executive order to lower prescription drug prices by fiat. Nothing is set in stone. But the order would reportedly index the government’s reimbursements for medicines to the prices that Britain, France, Canada, and other developed nations pay. Since all those nations ...
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
What We’re Watching – July 17
Rowena Itchon – 102-year-old woman survives 1918 pandemic, COVID-19 Gerri Schappals is 102, and survived the Spanish flu, cancer, and COVID-19 – an inspiration to us all. Ben Smithwick – The Black Swan Economy Jonathan Coslet, Senior Partner & Chief Investment Officer at TPG Capital, and Stanford Professor John B. ...
Coronavirus drug cost – Ignore critics. Here’s why the price is right
Last week, Gilead Sciences announced that it would sell a five-day course of its coronavirus drug, remdesivir, for just over $3,100. The antiviral, currently the only medication proven to speed recovery from COVID-19, received FDA approval in May. Some Democratic lawmakers and policy experts attacked remdesivir’s price as soon as it was announced. They claim that Gilead could sell the drug ...
Learning The Right Lessons From The Race For An Effective Covid-19 Treatment
On June 29, 2020 Gilead announced its price for remdesivir – an antiviral medication that has shown efficacy shortening the recovery time for patients with Covid-19. This price announcement provides several important lessons for the U.S. healthcare system. First, and perhaps most important, innovation is essential for winning the war against Covid-19. ...
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
What We’re Watching – June 19
Tim Anaya – How Medicines in the U.S. are Sold In the latest video in PRI’s “Escape the Drug Pricing Maze” video, the Professor and Pete reach the most difficult part of their journey: understanding how medicines are sold. It’s a complex system that hurts patients and at times exposes ...
What We’re Watching – June 5
Tim Anaya – Digging Up Ways to Lower Costs for High Value but Expensive Drugs In the latest video in the “Escape the Drug Pricing Maze” video, Sage the Detective Dog digs up clues on biologics and gene therapies – drugs that offer tremendous value for patients but are some ...